[go: up one dir, main page]

MX2018014929A - Conjugados de un agente farmaceutico y una porcion capaz de unirse a una proteina sensora de glucosa. - Google Patents

Conjugados de un agente farmaceutico y una porcion capaz de unirse a una proteina sensora de glucosa.

Info

Publication number
MX2018014929A
MX2018014929A MX2018014929A MX2018014929A MX2018014929A MX 2018014929 A MX2018014929 A MX 2018014929A MX 2018014929 A MX2018014929 A MX 2018014929A MX 2018014929 A MX2018014929 A MX 2018014929A MX 2018014929 A MX2018014929 A MX 2018014929A
Authority
MX
Mexico
Prior art keywords
pharmaceutical agent
binding
conjugates
moiety capable
glucose sensing
Prior art date
Application number
MX2018014929A
Other languages
English (en)
Inventor
Petry Stefan
Werner Ulrich
Plettenburg Oliver
Tennagels Norbert
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MX2018014929A publication Critical patent/MX2018014929A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/08—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals directly attached to carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/10—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals directly attached to heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/12—Acyclic radicals, not substituted by cyclic structures attached to a nitrogen atom of the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/056—Triazole or tetrazole radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)

Abstract

La invención describe conjugados novedosos de formula (I) de un agente farmacéutico y una porción capaz de unirse a una proteína censora de glucosa que permite una liberación reversible del agente farmacéutico que depende de la concentración de glucosa.
MX2018014929A 2016-06-02 2017-06-02 Conjugados de un agente farmaceutico y una porcion capaz de unirse a una proteina sensora de glucosa. MX2018014929A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16305640 2016-06-02
PCT/EP2017/063447 WO2017207754A1 (en) 2016-06-02 2017-06-02 Conjugates of a pharmaceutical agent and a moiety capable of binding to a glucose sensing protein

Publications (1)

Publication Number Publication Date
MX2018014929A true MX2018014929A (es) 2019-08-26

Family

ID=56121007

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018014929A MX2018014929A (es) 2016-06-02 2017-06-02 Conjugados de un agente farmaceutico y una porcion capaz de unirse a una proteina sensora de glucosa.

Country Status (13)

Country Link
US (3) US11090364B2 (es)
EP (1) EP3463480A1 (es)
JP (1) JP2019520342A (es)
KR (1) KR20190015413A (es)
CN (1) CN109562185A (es)
AU (1) AU2017272862A1 (es)
BR (1) BR112018074716A2 (es)
CA (1) CA3025988A1 (es)
IL (1) IL263390A (es)
MX (1) MX2018014929A (es)
RU (1) RU2018147235A (es)
SG (1) SG11201810701XA (es)
WO (1) WO2017207754A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109562185A (zh) * 2016-06-02 2019-04-02 赛诺菲 药剂与能够结合葡萄糖感应蛋白的部分的新颖缀合物
KR20200095507A (ko) 2017-12-01 2020-08-10 사노피 글루코오스 감지 단백질에 결합할 수 있는 모이어티 및 약제의 신규 접합체
KR20230152692A (ko) 2021-02-02 2023-11-03 리미널 바이오사이언시스 리미티드 Gpr84 길항제 및 이의 용도
CN115920081B (zh) * 2022-11-02 2024-07-19 重庆大学 红细胞膜自发定向包被ros响应的纳米前药及其应用
WO2025199666A1 (en) * 2024-03-25 2025-10-02 Canwell Biotech Limited Multivalent linkers for high loading antibody-drug conjugates, and compositions and methods thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK111489D0 (da) 1989-03-08 1989-03-08 Novo Nordisk As Peptider
WO2001092334A1 (en) 2000-06-02 2001-12-06 Novo Nordisk A/S Glucose dependent release of insulin from glucose sensing insulin derivatives
WO2003048195A2 (en) 2001-12-02 2003-06-12 Novo Nordisk A/S Glucose dependant release of insulin from glucose sensing insulin derivatives
EP2231191A2 (en) * 2007-12-11 2010-09-29 ConjuChem Biotechnologies Inc. Formulation of insulinotropic peptide conjugates
FR2929615B1 (fr) 2008-04-02 2010-12-17 Tfchem Composes c-aryl glycosides pour le traitement du diabete et de l'obesite.
CN101638423B (zh) 2008-07-29 2012-09-05 常州高新技术产业开发区三维工业技术研究所有限公司 根皮苷衍生物及其制备方法和用途
WO2010031813A1 (en) 2008-09-19 2010-03-25 Novartis Ag Glycoside derivatives and uses thereof
KR101635689B1 (ko) * 2009-01-28 2016-07-01 스마트쎌스, 인크. 제어 약물 전달을 위한 접합체 기재 시스템
RU2011135730A (ru) 2009-01-28 2013-03-10 Смартселлз, Инк. Кристаллические инсулин-коньюгаты
US8569231B2 (en) 2009-03-20 2013-10-29 Smartcells, Inc. Soluble non-depot insulin conjugates and uses thereof
WO2011000823A1 (en) 2009-06-30 2011-01-06 Novo Nordisk A/S Insulin derivatives
CN103037690B (zh) * 2010-03-24 2016-04-27 俄亥俄州立大学 用于葡萄糖转运抑制的组合物和方法
AU2011282977A1 (en) 2010-07-28 2013-02-21 Smartcells, Inc. Drug-ligand conjugates, synthesis thereof, and intermediates thereto
WO2012015692A2 (en) 2010-07-28 2012-02-02 Smartcells, Inc. Recombinantly expressed insulin polypeptides and uses thereof
CN103619862A (zh) 2011-04-14 2014-03-05 诺瓦提斯公司 糖苷衍生物及其用途
WO2012177701A2 (en) 2011-06-20 2012-12-27 Radiomedix Inc. Compositions, methods of synthesis and use of carbohydrate targeted agents
CN104271148A (zh) 2012-02-15 2015-01-07 洛桑聚合联合学院 红细胞结合性治疗剂
US20150086521A1 (en) 2012-03-21 2015-03-26 Erytech Pharma Medicament for the Treatment of Acute Myeloid Leukemia (AML)
WO2013182612A1 (en) * 2012-06-07 2013-12-12 Bayer Pharma Aktiengesellschaft Glucose transport inhibitors
EP2813234A1 (en) 2013-06-11 2014-12-17 Erytech Pharma Composition of erythrocytes encapsulating phenylalanine hydroxylase and therapeutic use thereof
TW201605470A (zh) 2013-10-04 2016-02-16 默沙東藥廠 葡萄糖反應性胰島素結合物
EP3094731B1 (en) 2014-01-15 2019-07-17 baseclick GmbH Saccharide-modified nucleic acid molecules
FR3017299B1 (fr) 2014-02-12 2018-05-18 Erytech Pharma Composition pharmaceutique comprenant des erythrocytes encapsulant une enzyme a plp et son cofacteur
CN108778318B (zh) * 2016-01-14 2022-05-03 北卡罗莱纳州立大学 葡萄糖响应性胰岛素递送组合物和方法
CN109562185A (zh) 2016-06-02 2019-04-02 赛诺菲 药剂与能够结合葡萄糖感应蛋白的部分的新颖缀合物

Also Published As

Publication number Publication date
WO2017207754A1 (en) 2017-12-07
AU2017272862A1 (en) 2019-01-17
US20210401947A1 (en) 2021-12-30
SG11201810701XA (en) 2018-12-28
BR112018074716A2 (pt) 2019-03-12
IL263390A (en) 2018-12-31
US20190209656A1 (en) 2019-07-11
CA3025988A1 (en) 2017-12-07
RU2018147235A (ru) 2020-07-10
KR20190015413A (ko) 2019-02-13
JP2019520342A (ja) 2019-07-18
US20210401946A1 (en) 2021-12-30
EP3463480A1 (en) 2019-04-10
CN109562185A (zh) 2019-04-02
US11090364B2 (en) 2021-08-17

Similar Documents

Publication Publication Date Title
MA41265B1 (fr) Compositions pour administration de médicaments iléo-jéjunal.
EP3700416A4 (en) PRE-CONNECTED ANALYSIS SENSORS
IL269690B (en) Conjugates containing an anthracycline drug-binding protein and their uses
HUE043338T2 (hu) Blautia hydrogenotrophica baktériumtörzset tartalmazó készítmények, a gyomor-bélrendszer bakteriális fertõzéseinek kezelésében történõ alkalmazásra
DK3576788T3 (da) Farmaceutisk sammensætning med lavt ph, der omfatter t-celle-engagerende antistofkontruktioner
DK3458102T3 (da) Anti-cmet-antistoflægemiddelkonjugater og fremgangsmåder til anvendelse deraf
PL3283521T3 (pl) Koniugaty leków zawierające przeciwciała przeciwko klaudynie 18.2
DK3478693T3 (da) Boronsyrederivater og terapeutiske anvendelser deraf
CL2014001930A1 (es) Formulacion farmacéutica que comprende un anticuerpo angiopoyetina 2 (anti-ang2).
DK3334500T3 (da) Multiligand-lægemiddelskonjugater og anvendelser deraf
MX2018014929A (es) Conjugados de un agente farmaceutico y una porcion capaz de unirse a una proteina sensora de glucosa.
BR112017028517A2 (pt) ?composição farmacêutica, vetor, peptídeo, polinucleotídeo e conjugado isolado e composição?
PH12016502061A1 (en) Novel antii-rnf43 antibodies and methods of use
EP3649932A4 (en) BIOLOGICAL INFORMATION MEASUREMENT CLOTHING
DK3412660T3 (da) Sulfonamidderivat og farmaceutisk sammensætning indeholdende samme
HUE046850T2 (hu) Új 2' és/vagy 5' aminosav észter foszforamidát 3'-deoxi adenozin származékok mint anti-rák vegyületek
IL273551A (en) Boronic acid derivatives and their synthesis
HUE055231T2 (hu) Inzulint tartalmazó gyógyászati készítmények
EA201791454A1 (ru) Лекарственные формы для трансдермального введения
GB201608936D0 (en) Novel conjugates and novel conjugating reagents
JOP20170115B1 (ar) مشتقات بيريدينيل، تركيبات صيدلية منها واستخداماتها كمثبطات aoc3
MA53732A (fr) Anticorps dirigés contre bcma soluble
MA32321B1 (fr) Pregn-4-en-21, 17 carbolactones substitués sur le noyau c, et préparations pharmaceutiques contenant ces derniers
MX372607B (es) Sal de succinato de citisina y uso de la misma
EP3605103A4 (en) MARKER FOR DETERMINING SENSITIVITY TO A COMBINED ANTI-CANCER MEDICINE